These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 21143906)
1. The position of mefloquine as a 21st century malaria chemoprophylaxis. Schlagenhauf P; Adamcova M; Regep L; Schaerer MT; Rhein HG Malar J; 2010 Dec; 9():357. PubMed ID: 21143906 [TBL] [Abstract][Full Text] [Related]
2. Mefloquine for preventing malaria during travel to endemic areas. Tickell-Painter M; Maayan N; Saunders R; Pace C; Sinclair D Cochrane Database Syst Rev; 2017 Oct; 10(10):CD006491. PubMed ID: 29083100 [TBL] [Abstract][Full Text] [Related]
3. Mefloquine at the crossroads? Implications for malaria chemoprophylaxis in Europe. Schlagenhauf P; Hatz C; Behrens R; Visser L; Funk M; Holzer B; Beck B; Bourquin C; Etter H; Furrer H; Genton B; Landry P; Chappuis F; Loutan L; Stössel U; Jeschko E; Rossanese A; Nothdurft HD Travel Med Infect Dis; 2015; 13(2):192-6. PubMed ID: 25825015 [TBL] [Abstract][Full Text] [Related]
4. Comparative benefit of malaria chemoprophylaxis modelled in United Kingdom travellers. Toovey S; Nieforth K; Smith P; Schlagenhauf P; Adamcova M; Tatt I; Tomianovic D; Schnetzler G Travel Med Infect Dis; 2014; 12(6 Pt B):726-32. PubMed ID: 25443997 [TBL] [Abstract][Full Text] [Related]
5. Mefloquine for malaria chemoprophylaxis 1992-1998: a review. Schlagenhauf P J Travel Med; 1999 Jun; 6(2):122-33. PubMed ID: 10381965 [TBL] [Abstract][Full Text] [Related]
6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
7. Failure of malaria chemoprophylaxis with mefloquine in an oversize traveller to Mozambique. Gobbi F; Rossanese A; Buonfrate D; Angheben A; Lunardi G; Bisoffi Z Malar J; 2013 Dec; 12():451. PubMed ID: 24350652 [TBL] [Abstract][Full Text] [Related]
8. Eye disorders reported with the use of mefloquine (Lariam(®)) chemoprophylaxis--A drug safety database analysis. Adamcova M; Schaerer MT; Bercaru I; Cockburn I; Rhein HG; Schlagenhauf P Travel Med Infect Dis; 2015; 13(5):400-8. PubMed ID: 26119539 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of a 3-day pretravel schedule of tafenoquine for malaria chemoprophylaxis: a network meta-analysis. Islam N; Wright S; Lau CL; Doi SAR; Mills DJ; Clark J; Clements ACA; Furuya-Kanamori L J Travel Med; 2021 Jul; 28(5):. PubMed ID: 33834208 [TBL] [Abstract][Full Text] [Related]
10. Mefloquine to prevent malaria: a systematic review of trials. Croft A; Garner P BMJ; 1997 Nov; 315(7120):1412-6. PubMed ID: 9418088 [TBL] [Abstract][Full Text] [Related]
11. Mefloquine for preventing malaria in non-immune adult travellers. Croft AM; Garner P Cochrane Database Syst Rev; 2000; (3):CD000138. PubMed ID: 10908460 [TBL] [Abstract][Full Text] [Related]
12. Controversies and misconceptions in malaria chemoprophylaxis for travelers. Chen LH; Wilson ME; Schlagenhauf P JAMA; 2007 May; 297(20):2251-63. PubMed ID: 17519415 [TBL] [Abstract][Full Text] [Related]